Abstract:
A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and/or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'-N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and/or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and/or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.
Abstract:
The invention is a method for enhancing the ability of absorbent materials, used transdermal patches and transdermal drug delivery devices, to liberate an active pharmaceutical substance from the transdermal delivery system.
Abstract:
The invention is a means to provide enhanced delivery of a drug from a transdermal patch, employing a screen filter at the bottom of the patch which contacts the skin. The screen filter enables the drag from the patch to become deposited onto the surface of the skin in a series of droplets, spaced in such a manner as to match the skin's pores. The drop deposition of the patch increases the speed of delivery of the patch, whether an active or a passive patch form.
Abstract:
The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
Abstract:
The present invention features, inter alia, pharmaceutical compositions and their use in the preparation of a medicament (e.g., a medicament for inflammation, such as an inflammatory lung disease) or in a therapeutic regimen. The compositions can include at least two active agents: a first agent that inhibits PDE4 (e.g., roflumilast) and a second active agent that inhibits the expression or activity of one or more PDE4B variants (e.g., PDE4B2). The compositions and methods will attenuate an unwanted up-regulation of a PDE4B (e.g., PDE4B2) and may thereby improve treatment with the first agent (e.g., roflumilast). For example, the second agent may improve the efficacy of the first agent, decrease the effective dose of the first agent, ameliorate the tolerance to the first agent that would otherwise develop (e.g., in patients with COPD exacerbation), reduce unwanted side effects caused by the first agent, or otherwise improve treatment regimes including a PDE4 inhibitor.
Abstract:
La presente invención se refiere a una composición farmacéutica conformada por baba de caracol Helix aspersa müller (Cryptophalus aspersus ) (20% a 50%), extracto de manzanilla (1-4%), propóleo (1-4%) y aditivos y/o excipientes farmacéuticamente aceptables para formar una formulación de viscosidad baja, intermedia o alta (10 a 1000 Pa-s). Dicha composición en forma de loción, jabón, crema o gel, embebido en tela tipo gasa en forma de parche para ser aplicada sobre lesiones de los diversos tipos de rosácea. La composición puede contener además extractos naturales tales como extracto de caléndula, miel y aceites vegetales. Se reivindica además el procedimiento de obtención de la composición y su uso para preparar un medicamento o dispositivo para prevenir, tratar o curar lesiones derivadas de la rosácea, en la piel del rostro o del cuerpo.
Abstract:
Apparatus and methods are provided to manage, prevent, and/or minimize tissue damage that elicits stretch marks and scars and more specifically to structures (e.g., a patch or patches) secured to the skin to provide controlled expansion of the underlying tissue.
Abstract:
The present invention relates to the treatment of wounds. More particularly, it relates to compounds according to Formula (1) for use in methods of promoting wound healing, to formulations which incorporate these compounds and to a method of treating wounds using such compounds and formulations: wherein R 1 and R 2 may be the same or different and are selected from the group consisting of hydrogen (H) and a physiologically hydrolysable chemical group consisting of alkyl, alkyl carbonyl, alkenylcarbonyl arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylether, alkenylether, arylether, and heteroarylether groups wherein the alkyl group or moiety consists of unsubstituted or substituted, straight-chain or branched-chain and cyclic alkyl groups having 2-22 carbon atoms, wherein the alkenyl moiety consists of unsubstituted and substituted, straight-chain or branched-chain and cyclic alkenyl groups having 2-22 carbon atoms, wherein the aryl moiety consists of unsubstituted and substituted phenyl, and phenalkyl groups wherein the alkyl moiety contains 1-3 carbon atoms and the phenyl moiety is unsubstituted or substituted, and the heteroaryl moiety is an aromatic 5- or 6-membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulphur.